A 38-year-old woman (JT) was diagnosed with posttransfusion purpura and significant posthysterectomy vaginal bleeding 9 days after the transfusion of 2 U of packed red blood cells. Analysis of JT's serum by a monoclonal antibodyantigen capture enzyme-linked immunosorbent assay method showed the presence of anti-HPA-5b (anti-Bra) antibodies directed against an epitope on platelet glycoprotein (GP) la of the GPla/lla complex. The patient's serum immunoprecipitated two proteins from '%labeled HPA-5b positive platelets that migrated under both nonreducing and reducing conditions on sodium dodecyl sulfate polyacrylamide gels at molecular weights characteristic of GPla (150 Kd and 165 Kd, respectively) and GPlla (120 Kd and 145 Kd, respectively).
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OSTTRANSFUSION purpura (PTP) is a severe immu-P nohematologic disorder that typically occurs 7 to 10 days after transfusion of packed red blood cells (RBCs) in patients with an otherwise normal platelet count.' Patients previously sensitized to a platelet-specific antigen, such as HPA-la (originally termed PIAL, see ref 2 for details of the new nomenclature system for platelet-specific antigens that will be used throughout this report) through pregnancy or transfusion develop an "anamnestic" antibody response to this antigen that is carried by the platelets present in the unit of transfused RBCs. The striking feature of this disorder is that the patient's own nonallogeneic platelets are destroyed, resulting in profound thrombocytopenia with platelet counts typically falling below 10 X 10y/L (normal range, 150 to 450 x 109/L). The condition is frequently accompanied with significant morbidity' and even mortality3 due to hemorrhage.
The antibody most often associated with PTP is anti-HPA-la,L.4 which is directed against an alloantigenic epitope located on glycoprotein (GP) IIIa of the GPIIb/IIIa complex.' In addition to anti-HPA-la, anti-HPA-lb, or antianti-HPA-3a or anti-Bar,' anti-HPA-3b or antiBakb,*,' and anti-HPA-4a or anti-PenaLo have also been found to occasionally induce PTP. All of these alloantigens are located on GPIIb or GPIIIa, of which there are -40,000 to 50,000 molecules present on the platelet surIn contrast, no clear evidence for PTP induced by antibodies directed against the newly described alloantigens, HPA-Sa (Brb) and HPA-Sb (Bra),14 has been reported. Unlike the previously characterized alloantigens associated with PTP, HPA-Sa and HPA-Sb are located on GPIa of the GPIa/IIa complex,L4 for which there are -1,000 to 2,000 molecules expressed on the platelet ~urface.'~ Due to the considerably lower density of GPIaiIIa as compared with GPIIb/IIIa, questions have been raised as to whether antibodies produced in adult patients that are directed against HPA-Sa and HPA-Sb can provoke clinically significant hemorrhagic symptoms. In this report we describe a patient who developed PTP that was provoked by anti-HPA-Sb and was associated with significant postsurgical bleeding.
These bands were not precipitated when 'r51-labeled HPA-5b negative platelets were used. Platelet typings performed on JT and her three children showed that the patient was HPAdb negative and one of her children was HPA-5b positive. Platelets obtained from one of the donors who provided blood for the inciting transfusion also typed as HPAdb positive. These findings demonstrate that posttransfusion purpura may be induced by antibodies directed against an alloantigenic epitope, namely HPA-5b (Br"), located on GPla/ Ila. Moreover, clinically significant bleeding can be associated with antibody reactions directed against this GP complex.
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MATERIALS AND METHODS
JT, a 38-year-old white woman (gravida 3ipara 3) was admitted for elective hysterectomy on November 17, 1988 . She was iron deficient and intolerant of oral iron. Laboratory tests at the time of admission showed a hemoglobin count of 8.7 gidL, hematocrit of 28.8%, white blood cells (WBCs) at 15.2 X lo9& and platelets at 203 X 109iL. The patient's gynecologist elected to transfuse her with 2 U of packed RBCs (unwashed) the evening (November 18, 1988) before surgery, even though she was young and had no cardiorespiratory problems. She was discharged 4 days later without complications. On November 27,1988 the patient was readmitted with heavy vaginal bleeding, including large clots. There were no other sites of bleeding and no petechiae or ecchymoses except at previous venipuncture sites. Laboratory tests then showed a hemoglobin count of 8.3 g/dL, hematocrit of 33.9%, WBCs at 14.4 x 109iL, and platelets at 26 x 109/L. Prothrombin time was 12.6 seconds, partial thromboplastin time (PTT) was 24.8 seconds, and the fibrinogen level was 339 mg/dL, all of which were within normal ranges. Peripheral smear was remarkable only for large platelets and small pale RBCs. Due to continued bleeding, the patient received 8 U of random donor platelets on the night of November 27, 1988 (Fig 1) . The following morning, the platelet count was 40 X 109iL. No adverse reaction occurred with these transfused platelets. Prednisone (initially at 80 mgid and then rapidly tapered to 40 mgid) was administered to the patient on Tony Hunter, The Salk Institute. La Jolla. CA) directed against GPla (see Fig 3) . This latter antihody has similar specificity to 12Fl." Alloantibodies for platelet typing were obtained from patients with PTP. individuals after receiving multiple platelet transfusions. or women allaimmunized through pregnancy (all identified by the University of Minnesota Platelet Serology Laboratory). Anti-HPA-3a (anti-Bak') was kindly provided hy Dr R.
Nordhagen (Oslo, Norway) and anti-HPA-Sa (anti-Rf) hy Dr C.
Mueller-Eskhardt (Giessen. Germany). Additional studies by immunoprecipitation demonstrated that the alloantibody present in JT's acute and convalescent sera, as well as MoAbs 12F1 and B1.515, reacted with two protein bands with nonreduced molecular weights of 150 Kd and 120 Kd (lanes 2 and 3) and reduced molecular weights of 165 Kd and 145 Kd (lanes 9 and IO), which were characteristic of this gel system and consistent with the previously reported molecular weights for GPIa and GPIIa,'s.26 respectively (Fig 3) . Both AP3 and anti-HPA-la precipitated two bands consistent in mobility with those of GPIlb and GPlIIa (lanes 4, 7, 11, 14, 18, and 21 ) from each of the two donors under reduced and nonreduced conditions. No specific reactions with protein bands characteristic of GPIIb and/or GPlIIa or other surface molecules were detected using J T s serum. In agreement with the MAIPA results, the patient's antibody immunoprecipitated only with HPA-Sb positive (lanes 2, 3, 9, and 10) and not with HPA-Sb negative (lanes 16 and 17) platelets.
RESULTS

Analysis
Platelet-typing studies were performed for the HPA-la, HPA-lb, HPA-3a. HPA-3b, HPA-Sa, and HPA-Sb antigens with platelets from patient JT, her three children (RT, AT, and BT), and one of the original two RBC donors. Patient JT typed as HPA-la/b, HPA3a/a, and HPA-Sa/a ( Table 1) . Antigen incompatibility was detected in two of the children: RT typed as HPA3ab and, thus, could have sensitizcd JT to the HPA-3b antigen, and AT typed as HPA-Sa/b and, thus, could have sensitized JT to the HPA-Sb antigen. Antigen incompatibility was also detected with the donor's platelets that typcd as HPA-Sa/b. Furthcr evidencc for HPA-Sb incompatibility between JT and AT and the donor 515 (12, 15, end 19) . anti-GPIa MoAb 12F1 (6, 13,  and 20) . or anti-GPilla MoAb AP3 (7, 14, and 21). Following washing, platelets were aolubilized and the antigen-antibody complexes isolated with protein A-Sepharose as described in Materials and Methoda. Immune complexes were solubilized in SDS under either nonreducing (1 through 7) or reducing (8 through 21) conditions and electrophoresed on 7.5% SDS-PAGE, dried, and exposed to x-ray film at -80°F for 1 to 4 days.
was obtained by performing cross-matches between J T s serum and platelets from her children and the donor. Using the MAIPA procedure and the GPIa/IIa-specific MoAb B1.515, positive reactions were only detected with platelets from AT, the donor, and a known HPA-Sb positive control (Fig 4) .
DISCUSSION
Two important findings emerge from this study: (1) PTP may be induced by anti-HPA-Sb (anti-Br') antibodies; and (2) reaction of an alloantibody with the GPIa/IIa complex may be accompanied by significant hemorrhagic symptoms. Several lines of evidence support these conclusions, including the onset in patient JT of severe thrombocytopenia For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From HPA-la/b, HPA-3a/a, HPA-5a/a HPA-la/a, HPA-3a/b, HPA-5a/a HPA-laib, HPA-3a/a, HPA-Sa/b HPA-la/b, HPA-3a/a, HPA-5a/a HPA-3a/a, HPA-5a/bt *Platelet antigen typings were performed by the MAIPA assay using defined alloantisera and MoAbs directed against GPllla (AP3) for the HPA-la, HPA-lb, HPA-3a, and HPA-3b antigens and GPla (81.515) for the HPA-5a and HPA-5b antigens. HPA-3a typings with RT, AT, and BT platelets were performed by immunoflourescence.
tThe donor was only typed for the H P A J and HPA-5 antigens because JTtyped as HPA-la/b. aware of only one publication attributing PTP to HLA antibodies, and no assays for detection of platelet-specific antibodies were performed in that case.27 Importantly, although the role of HLA antibodies in PTP is not clearly understood, all true cases of PTP appear to be associated with platelet-specific antibodies that may or may not include the presence of HLA antibodies.'.z8329 There is a single previous report of anti-Zavb (identical to anti-HPASa) in association with PTP. However, it is significant that the patient also possessed anti-HPA-3a antib~dies,~' which are known to be associated with PTP7; consequently, the role of anti-Zavb in this disorder could not be ascertained. Thus, the present study appears to provide the first definitive evidence for platelet-specific alloantibodies reacting only with the GPIa/IIa complex involved in precipitating PTP, and that were also associated with clinically significant problems.
The original report of anti-HPA-Sb involved four cases of children born with neonatal alloimmune thrombocytoper~ia.~' Although platelet counts in the affected newborns ranged from 19 x 10y/L to 75 x 10y/L, none of these patients experienced hemorrhagic symptoms. In another study, anti-Hca, which is identical to anti-HPA-Sb, was detected in the serum of two patients with systemic lupus erythemato~us.~~ In neither of these patients was any bleeding associated with the presence of the alloantibodies. However, clinical significance for anti-HPA-Sa and -5b has been demonstrated in several polytransfused who developed these antibodies and subsequently became refractory to platelet transfusion, Although these reports do not document the presence of bleeding in the affected patients, it is well known that prolonged lack of response to platelet transfusion is frequently associated with major bleeding complications. . It is estimated that 200 to 300 molecules of bound antibody per platelet are sufficient to provoke platelet destruction in vivo34; thus, 1,000 to 2,000 molecules of HPA-Sb per platelett4 should provide adequate antigen density for attachment of anti-HPA-5b and subsequent initiation of thrombocytopenia. Drawing on these observations and the fact that sensitive techniques such as antigen-capture methods are needed for detection of alloantibodies against GPIa and/or IIa, it seems reasonable to anticipate that additional cases of PTP due to anti-HPA-Sb may occur. It is even possible that anti-HPA-Sb could account for prior cases of PTP in which no platelet-specific antibodies were detected.
